Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaOmid Hamid, Antoni Ribas, Caroline Robert et al.|New England Journal of Medicine|2013Cited by 3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Adil Daud, Antoni Ribas et al.|The Lancet|2014Cited by 1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Caroline Robert, Scot Ebbinghaus et al.|JAMA|2016Cited by 1.1k
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF. Stephen Hodi, Jedd D. Wolchok, Wen-Jen Hwu et al.|Journal of Clinical Oncology|2016Cited by 754
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil Daud, Omid Hamid, Jedd D. Wolchok et al.|Journal of Clinical Oncology|2016Cited by 679